Scaling point-of-care test to combat antimicrobial resistance in ANZ

Antimicrobial resistance (AMR) stands as a critical global threat to public health, primarily driven by the misuse and overuse of antimicrobials, and the development of drug-resistant pathogens. Lumos Diagnostics has taken a significant step in combatting this issue by securing an agreement with Regional Health Care Group (RHCG) in Australia and New Zealand, to distribute their FebriDx point-of-care test.

This test effectively distinguishes between viral and bacterial acute respiratory infections, aiding healthcare professionals in making rapid and accurate treatment decisions.

The collaboration marks an expansion of FebriDx’s reach through Henry Schein’s extensive Medical business network, now encompassing Australia and New Zealand. RHCG, a pivotal arm of Henry Schein, the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, will spearhead the distribution efforts.

Mike Covey, Vice President of Henry Schein for the APAC Region and Managing Director in Australia, stated “At Henry Schein, our goal is to help health care professionals enhance efficiencies through practice care so they can focus on delivering quality patient care. We are therefore delighted to expand our distribution of FebriDx beyond Portugal, Spain, the Netherlands, the United Kingdom, and the United States to now include Australia and New Zealand.”

FebriDx delivers results within 10 minutes from a simple fingerstick blood sample, facilitating swift and accurate management of infectious patients across Primary Care, Urgent Care, Emergency Departments, Paediatric facilities, and other outpatient settings. RHCG has already commenced sales and marketing initiatives to introduce FebriDx across ANZ.

“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said Doug Ward, CEO of Lumos Diagnostics.

“Henry Schein has been a terrific  and  supportive  partner  for  Lumos  across  Europe.  With  our  recent  U.S.  launch  and  the  growing commercial  interest  in  FebriDx,  we  are  now  preparing  production  of  FebriDx  to  meet  the  anticipated growing  demand  for  the  product,  to  support our  customers.  It  is very exciting  to  have  Henry  Schein  as part  of  this  strategy  with  their  expanded  distribution  coverage  for  FebriDx  in  the  Australian  and  New Zealand markets.”  

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.